These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

760 related items for PubMed ID: 18490431

  • 1. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate.
    Wells G, Becker JC, Teng J, Dougados M, Schiff M, Smolen J, Aletaha D, van Riel PL.
    Ann Rheum Dis; 2009 Jun; 68(6):954-60. PubMed ID: 18490431
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate.
    Schiff M, Keiserman M, Codding C, Songcharoen S, Berman A, Nayiager S, Saldate C, Li T, Aranda R, Becker JC, Lin C, Cornet PL, Dougados M.
    Ann Rheum Dis; 2008 Aug; 67(8):1096-103. PubMed ID: 18055472
    [Abstract] [Full Text] [Related]

  • 3. Comparison of the disease activity score using the erythrocyte sedimentation rate and C-reactive protein levels in Koreans with rheumatoid arthritis.
    Son KM, Kim SY, Lee SH, Yang CM, Seo YI, Kim HA.
    Int J Rheum Dis; 2016 Dec; 19(12):1278-1283. PubMed ID: 26200604
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The multi-biomarker disease activity score tracks response to rituximab treatment in rheumatoid arthritis patients: a post hoc analysis of three cohort studies.
    Roodenrijs NMT, de Hair MJH, Wheater G, Elshahaly M, Tekstra J, Teng YKO, Lafeber FPJG, Hwang CC, Liu X, Sasso EH, van Laar JM.
    Arthritis Res Ther; 2018 Nov 20; 20(1):256. PubMed ID: 30458871
    [Abstract] [Full Text] [Related]

  • 7. Evaluation of Response Criteria in Rheumatoid Arthritis Treated With Biologic Disease-Modifying Antirheumatic Drugs.
    Inoue M, Kanda H, Tateishi S, Fujio K.
    Arthritis Care Res (Hoboken); 2020 Jul 20; 72(7):942-949. PubMed ID: 31058442
    [Abstract] [Full Text] [Related]

  • 8. Comparison of the DAS28-CRP and DAS28-ESR in patients with rheumatoid arthritis.
    Sengul I, Akcay-Yalbuzdag S, Ince B, Goksel-Karatepe A, Kaya T.
    Int J Rheum Dis; 2015 Jul 20; 18(6):640-5. PubMed ID: 26013310
    [Abstract] [Full Text] [Related]

  • 9. How much does Disease Activity Score in 28 joints ESR and CRP calculations underestimate disease activity compared with the Simplified Disease Activity Index?
    Fleischmann R, van der Heijde D, Koenig AS, Pedersen R, Szumski A, Marshall L, Bananis E.
    Ann Rheum Dis; 2015 Jun 20; 74(6):1132-7. PubMed ID: 25143522
    [Abstract] [Full Text] [Related]

  • 10. High Proportion of Subjective Component to the Disease Activity Score is Associated with Favorable Response to Abatacept in Rheumatoid Arthritis.
    Lee JS, Ahmad H, Shim SC, Bae SC, Song YW, Lee EY.
    Patient; 2019 Jun 20; 12(3):319-326. PubMed ID: 30484084
    [Abstract] [Full Text] [Related]

  • 11. Abatacept plus methotrexate provides incremental clinical benefits versus methotrexate alone in methotrexate-naive patients with early rheumatoid arthritis who achieve radiographic nonprogression.
    Wells AF, Westhovens R, Reed DM, Fanti L, Becker JC, Covucci A, Keystone EC.
    J Rheumatol; 2011 Nov 20; 38(11):2362-8. PubMed ID: 21885491
    [Abstract] [Full Text] [Related]

  • 12. Remission in rheumatoid arthritis by different criteria does not converge over the inflammatory markers.
    Chandrashekara S, Priyanka BU.
    Int J Rheum Dis; 2013 Jun 20; 16(3):291-6. PubMed ID: 23981750
    [Abstract] [Full Text] [Related]

  • 13. Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry.
    Leffers HC, Ostergaard M, Glintborg B, Krogh NS, Foged H, Tarp U, Lorenzen T, Hansen A, Hansen MS, Jacobsen MS, Dreyer L, Hetland ML, all departments of rheumatology in Denmark.
    Ann Rheum Dis; 2011 Jul 20; 70(7):1216-22. PubMed ID: 21551512
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Proposed severity and response criteria for Routine Assessment of Patient Index Data (RAPID3): results for categories of disease activity and response criteria in abatacept clinical trials.
    Pincus T, Hines P, Bergman MJ, Yazici Y, Rosenblatt LC, MacLean R.
    J Rheumatol; 2011 Dec 20; 38(12):2565-71. PubMed ID: 22089467
    [Abstract] [Full Text] [Related]

  • 19. RAPID3 (Routine Assessment of Patient Index Data 3) severity categories and response criteria: Similar results to DAS28 (Disease Activity Score) and CDAI (Clinical Disease Activity Index) in the RAPID 1 (Rheumatoid Arthritis Prevention of Structural Damage) clinical trial of certolizumab pegol.
    Pincus T, Furer V, Keystone E, Yazici Y, Bergman MJ, Luijtens K.
    Arthritis Care Res (Hoboken); 2011 Aug 20; 63(8):1142-9. PubMed ID: 21485024
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.